News

FDA action extends Kuvan’s market exclusivity to June 2015 and is based on trials submitted in response to a written request by the FDA to investigate the use

If FDA approves the combination tablet, it will bring together the distinct mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.

The company said that initial target indication is pain management for patients suffering from oral mucositis during cancer therapy. In several pilot studies, Oracain has produced promising clinical

Dr James Andrews will act as principal investigator for the study. Dr Andrews is a founding partner and medical director for the Andrews Institute in Gulf Breeze, Florida.

This milestone adds to ProTrials’ successful track record in supporting ophthalmology studies investigating new treatments for a broad range of eye conditions, from age-related macular degeneration (AMD) to

After a thorough evaluation process of various commercially available technologies, Surrey CRC selected Promasys technology to manage its clinical research activities. Promasys ranked highest across all categories including

ESR, a common laboratory test and measure of inflammation, describes the rate at which red blood cells (RBC) travel through anti-coagulated blood. When an inflammatory process is present,

The settlements permit the defendants to begin selling generic versions of Gralise on 1 January 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the

These patents will provide protection in Japan until 2030. Including these patents, Advaxis now has well over 40 patents issued and over 40 patents pending worldwide, all covering